Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: DrugBank:EXPT01586 (
G418
)
2,237
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The matricellular protein
CCN1
is significantly elevated in acutely ultraviolet-irradiated human skin and negatively regulates collagen homeostasis by suppressing collagen synthesis and increasing collagen degradation. In this study, we established a stable cell line, termed
CCN1
-GFs, by transfection of the pAcGFP1-1-
CCN1
promoter plasmid and examined its usefulness as a cell-based assay system for screening anti-aging ingredients. The promoter of the reporter plasmid pAcGFP1-1-
CCN1
promoter was transfected into NIH3T3 cells using the Lipofectamine reagent.
G418
-resistant cells were selected and further cloned. To confirm whether AcGFP1-1-
CCN1
promoter plasmid recombined in the NIH3T3 cells, the level of AcGFP1-1-
CCN1
was measured by PCR analysis. To determine if NIH3T3 cells expressed the gene encoding green fluorescence protein in a
CCN1
promoter-dependent manner, the reporter enzyme activities were assayed using a fluorimeter and flow cytometer. To determine if
CCN1
inhibitor, which was selected through this system, exerted a direct effect on the downstream signal, mRNA expression of collagen1 and MMP1A was checked by using real-time PCR. UVB irradiation of
CCN1
-GFs resulted in increased
CCN1
promoter activity. Treatment with retinoic acid, a
CCN1
inhibitor, inhibited UV-induced
CCN1
promoter activity. Subsequent use of this assay system to screen anti-aging ingredients revealed that
CCN1
-GFs treated with sclareol showed decreased levels of UVB-induced
CCN1
expression. Sclareol attenuated UVB-induced photo-aging by an increase in collagen synthesis and decrease in MMP-1 activity.
...
PMID:Cell-based assay system for high-throughput screening of anti-photo-aging agents in fibroblast transfectants. 2628 1